Nicox (ALCOX.PA) Stock Price

Nicox Price

Euronext·CLOSED
0.38EUR-0.0065 (-1.72 %)
Market closed

Revenue has compounded at 1.0% per year over the past 19 years to 7.86 M EUR. Nicox's net margin stands at -279.9%, down from -125.5% several years earlier. Analysts set a median price target of 1.53 EUR, implying 307.5% above the current price. Of 9 analysts, 8 rate the stock a buy — an overall Buy consensus. The stock trades about 32% above its 52-week low.

Nicox stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Nicox over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Nicox stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Nicox's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Nicox Stock Price History
DateNicox Price
7/24/20260.38 EUR
7/23/20260.38 EUR
7/22/20260.38 EUR
7/21/20260.38 EUR
7/20/20260.37 EUR
7/17/20260.38 EUR
7/16/20260.38 EUR
7/15/20260.38 EUR
7/14/20260.39 EUR
7/13/20260.40 EUR
7/10/20260.38 EUR
7/9/20260.39 EUR
7/8/20260.39 EUR
7/7/20260.39 EUR
7/6/20260.39 EUR
7/3/20260.38 EUR
7/2/20260.38 EUR
7/1/20260.37 EUR
6/30/20260.38 EUR
6/29/20260.37 EUR
6/26/20260.37 EUR
6/25/20260.37 EUR
6/24/20260.38 EUR
6/23/20260.37 EUR
6/22/20260.38 EUR
6/19/20260.39 EUR
6/18/20260.38 EUR
6/17/20260.37 EUR
6/16/20260.36 EUR
6/15/20260.37 EUR
6/12/20260.35 EUR
6/11/20260.35 EUR
6/10/20260.36 EUR
6/9/20260.37 EUR
6/8/20260.37 EUR
6/5/20260.37 EUR
6/4/20260.38 EUR
6/3/20260.38 EUR
6/2/20260.38 EUR
6/1/20260.38 EUR
5/29/20260.38 EUR
5/28/20260.39 EUR
5/27/20260.39 EUR
5/26/20260.39 EUR
5/25/20260.39 EUR
5/22/20260.39 EUR
5/21/20260.39 EUR
5/20/20260.39 EUR
5/19/20260.38 EUR
5/18/20260.39 EUR
5/15/20260.38 EUR
5/14/20260.38 EUR
5/13/20260.38 EUR
5/12/20260.38 EUR
5/11/20260.37 EUR
5/8/20260.38 EUR
5/7/20260.38 EUR
5/6/20260.39 EUR
5/5/20260.38 EUR
5/4/20260.39 EUR
4/30/20260.39 EUR
4/29/20260.40 EUR
4/28/20260.40 EUR
4/27/20260.40 EUR
4/24/20260.41 EUR
4/23/20260.41 EUR
4/22/20260.40 EUR
4/21/20260.41 EUR
4/20/20260.41 EUR
4/17/20260.43 EUR
4/16/20260.41 EUR
4/15/20260.41 EUR
4/14/20260.41 EUR
4/13/20260.40 EUR
4/10/20260.41 EUR
4/9/20260.42 EUR
4/8/20260.43 EUR
4/7/20260.41 EUR
4/2/20260.41 EUR
4/1/20260.41 EUR
3/31/20260.39 EUR
3/30/20260.39 EUR
3/27/20260.40 EUR
3/26/20260.41 EUR
3/25/20260.42 EUR
3/24/20260.40 EUR
3/23/20260.41 EUR
3/20/20260.41 EUR
3/19/20260.41 EUR
3/18/20260.43 EUR
3/17/20260.42 EUR
3/16/20260.42 EUR
3/13/20260.43 EUR
3/12/20260.43 EUR
3/11/20260.44 EUR
3/10/20260.45 EUR
3/9/20260.44 EUR
3/6/20260.45 EUR
3/5/20260.45 EUR
3/4/20260.46 EUR
3/3/20260.42 EUR
3/2/20260.48 EUR
2/27/20260.48 EUR
2/26/20260.47 EUR
2/25/20260.51 EUR
2/24/20260.50 EUR
2/23/20260.41 EUR
2/20/20260.41 EUR
2/19/20260.42 EUR
2/18/20260.39 EUR
2/17/20260.41 EUR
2/16/20260.41 EUR
2/13/20260.39 EUR
2/12/20260.38 EUR
2/11/20260.37 EUR
2/10/20260.37 EUR
2/9/20260.35 EUR
2/6/20260.34 EUR
2/5/20260.35 EUR
2/4/20260.36 EUR
2/3/20260.36 EUR
2/2/20260.37 EUR
1/30/20260.36 EUR
1/29/20260.37 EUR
1/28/20260.37 EUR
1/27/20260.36 EUR
1/26/20260.37 EUR
1/23/20260.39 EUR
1/22/20260.35 EUR
1/21/20260.34 EUR
1/20/20260.34 EUR
1/19/20260.34 EUR
1/16/20260.35 EUR
1/15/20260.35 EUR
1/14/20260.34 EUR
1/13/20260.34 EUR
1/12/20260.35 EUR
1/9/20260.34 EUR
1/8/20260.35 EUR
1/7/20260.36 EUR
1/6/20260.36 EUR
1/5/20260.35 EUR
1/2/20260.31 EUR
12/31/20250.30 EUR
12/30/20250.29 EUR
12/29/20250.30 EUR
12/24/20250.30 EUR
12/23/20250.29 EUR
12/22/20250.29 EUR
12/19/20250.28 EUR
12/18/20250.29 EUR
12/17/20250.29 EUR
12/16/20250.29 EUR
12/15/20250.29 EUR
12/12/20250.29 EUR
12/11/20250.30 EUR
12/10/20250.29 EUR
12/9/20250.29 EUR
12/8/20250.30 EUR
12/5/20250.30 EUR
12/4/20250.30 EUR
12/3/20250.30 EUR
12/2/20250.31 EUR
12/1/20250.30 EUR
11/28/20250.30 EUR
11/27/20250.31 EUR
11/26/20250.30 EUR
11/25/20250.30 EUR
11/24/20250.30 EUR
11/21/20250.30 EUR
11/20/20250.31 EUR
11/19/20250.31 EUR
11/18/20250.32 EUR
11/17/20250.33 EUR
11/14/20250.33 EUR
11/13/20250.33 EUR
11/12/20250.34 EUR
11/11/20250.33 EUR
11/10/20250.32 EUR
11/7/20250.32 EUR
11/6/20250.32 EUR
11/5/20250.33 EUR
11/4/20250.33 EUR
11/3/20250.34 EUR
10/31/20250.34 EUR
10/30/20250.34 EUR
10/29/20250.35 EUR
10/28/20250.35 EUR
10/27/20250.36 EUR
10/24/20250.36 EUR
10/23/20250.36 EUR
10/22/20250.35 EUR
10/21/20250.34 EUR
10/20/20250.34 EUR
10/17/20250.35 EUR
10/16/20250.35 EUR
10/15/20250.35 EUR
10/14/20250.34 EUR
10/13/20250.35 EUR
10/10/20250.36 EUR
10/9/20250.36 EUR
10/8/20250.35 EUR
10/7/20250.36 EUR
10/6/20250.37 EUR
10/3/20250.37 EUR
10/2/20250.36 EUR
10/1/20250.38 EUR
9/30/20250.36 EUR
9/29/20250.36 EUR
9/26/20250.37 EUR
9/25/20250.37 EUR
9/24/20250.38 EUR
9/23/20250.36 EUR
9/22/20250.37 EUR
9/19/20250.38 EUR
9/18/20250.37 EUR
9/17/20250.36 EUR
9/16/20250.36 EUR
9/15/20250.37 EUR
9/12/20250.37 EUR
9/11/20250.37 EUR
9/10/20250.37 EUR
9/9/20250.35 EUR
9/8/20250.34 EUR
9/5/20250.36 EUR
9/4/20250.32 EUR
9/3/20250.32 EUR
9/2/20250.33 EUR
9/1/20250.34 EUR
8/29/20250.36 EUR
8/28/20250.37 EUR
8/27/20250.37 EUR
8/26/20250.36 EUR
8/25/20250.38 EUR
8/22/20250.37 EUR
8/21/20250.40 EUR
8/20/20250.43 EUR
8/19/20250.46 EUR
8/18/20250.48 EUR
8/15/20250.49 EUR
8/14/20250.49 EUR
8/13/20250.53 EUR
8/12/20250.53 EUR
8/11/20250.55 EUR
8/8/20250.53 EUR
8/7/20250.62 EUR
8/6/20250.52 EUR
8/5/20250.46 EUR
8/4/20250.38 EUR
8/1/20250.33 EUR
7/31/20250.35 EUR
7/30/20250.36 EUR
7/29/20250.37 EUR
Access this data via the Eulerpool API
Get Free API Key

Nicox Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
14.42 M EUR
-7.01 M EUR
-18.10 M EUR
Jan 1, 2021
8.58 M EUR
-42.61 M EUR
-43.76 M EUR
Jan 1, 2022
5.24 M EUR
-28.71 M EUR
-27.76 M EUR
Jan 1, 2023
6.90 M EUR
-17.84 M EUR
-21.00 M EUR
Jan 1, 2024
7.86 M EUR
-36.00 M EUR
-22.00 M EUR
Jan 1, 2025 (e)
16.20 M EUR
-12.86 M EUR
-884,400.00 EUR
Jan 1, 2026 (e)
3.00 M EUR
-2.38 M EUR
-6.19 M EUR
Jan 1, 2027 (e)
10.00 M EUR
-7.94 M EUR
884,400.00 EUR

Nicox Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 28, 2026, 11:45 AM
 
REVENUEM EUR
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM EUR
EBITM EUR
EBIT MARGIN%
NET INCOMEM EUR
NET INCOME GROWTH%
SHARESM
20122013201420152016201720182019202020212022202320242025e2026e2027e
7.00–5.009.00–15.004.008.0014.008.005.006.007.0016.003.0010.00
–––80.00––-73.33100.0075.00-42.86-37.5020.0016.67128.57-81.25233.33
100.00–40.0044.44–13.33100.0075.0085.7187.5060.0050.0042.8660.0060.0060.00
7.003.002.004.003.002.004.006.0012.007.003.003.003.009.601.806.00
-8.00-17.00-21.00-28.00-7.00-18.00-20.00-18.00-7.00-42.00-28.00-17.00-36.00-12.00-2.00-7.00
-114.29–-420.00-311.11–-120.00-500.00-225.00-50.00-525.00-560.00-283.33-514.29-75.00-66.67-70.00
-10.00-17.00-15.00-27.00-19.00-3.00-18.00-18.00-18.00-43.00-27.00-21.00-22.00–-6.00–
-37.5070.00-11.7680.00-29.63-84.21500.00––138.89-37.21-22.224.76–––
69.0069.0069.0069.0069.0069.0069.0069.0069.0069.0044.7450.0069.0069.0069.0069.00
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Nicox generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Nicox retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Nicox's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Nicox has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Nicox's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Nicox stock margins

The Nicox margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Nicox. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Nicox.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
89.49 %
-48.62 %
-125.48 %
Jan 1, 2021
84.27 %
-496.41 %
-509.86 %
Jan 1, 2022
62.40 %
-547.65 %
-529.55 %
Jan 1, 2023
62.40 %
-258.42 %
-304.22 %
Jan 1, 2024
62.40 %
-458.02 %
-279.90 %
Jan 1, 2025 (e)
62.40 %
-79.36 %
-5.46 %
Jan 1, 2026 (e)
62.40 %
-79.36 %
-206.36 %
Jan 1, 2027 (e)
62.40 %
-79.36 %
8.84 %

Nicox Stock Revenue, EBIT, Earnings per Share

The Nicox earnings per share therefore indicates how much revenue Nicox has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
0.00 EUR
0.00 EUR
0.00 EUR
Jan 1, 2021
0.00 EUR
0.00 EUR
0.00 EUR
Jan 1, 2022
0.12 EUR
-0.64 EUR
-0.62 EUR
Jan 1, 2023
0.14 EUR
-0.36 EUR
-0.42 EUR
Jan 1, 2024
0.11 EUR
-0.52 EUR
-0.32 EUR
Jan 1, 2025 (e)
0.18 EUR
-0.19 EUR
-0.01 EUR
Jan 1, 2026 (e)
0.03 EUR
-0.03 EUR
-0.07 EUR
Jan 1, 2027 (e)
0.11 EUR
-0.12 EUR
0.01 EUR

Nicox business model & stock analysis

Nicox SA is a French pharmaceutical company specializing in the development and commercialization of innovative therapy systems for eye diseases. It was founded in 1996 as a spin-off of Nestlé's research activities in the field of ophthalmology. The company's business model is based on the development of drugs based on nitric oxide (NO), a gaseous molecule that plays an important role in regulating blood flow and inflammation processes in the human body. Nicox SA's technology allows for the targeted release of NO donors in specific areas of the eye to reduce disease-related inflammation and damage. This provides a promising alternative to conventional therapies for a range of eye diseases. Nicox SA is divided into three business areas: Ophthalmology, Diagnostics, and Contracts. In the Ophthalmology segment, the company focuses on the development of drugs for the treatment of glaucoma, dry eye, and other eye diseases. Important products in this area include Vyzulta, a combination of an NO donor and a glaucoma drug, as well as NCX 470, an NO donor for the treatment of glaucoma. In addition, the company is working on the development of NCX 4251, an NO donor for the treatment of blepharitis, an inflammation of the eyelids. In the Diagnostics segment, Nicox SA offers innovative diagnostic tests for ophthalmology based on tear fluid analysis. These tests enable ophthalmologists to diagnose and monitor certain eye diseases more quickly and accurately. Key products in this area include AdenoPlus, a rapid test for diagnosing adenovirus conjunctivitis, and ClearSight, a test for monitoring glaucoma patients. The Contracts segment offers customized clinical research services for customers in the pharmaceutical industry. This segment is an important part of Nicox SA's strategy to generate additional revenue and finance the development of new therapies. Overall, Nicox SA has a strong pipeline of new therapies and diagnostic tests that allow the company to consolidate its position as a leading provider of eye medications. The company works closely with its industry and academic research partners to develop and bring innovative therapies to the market. In summary, Nicox SA is an innovative and rapidly growing company focusing on the development and commercialization of therapies for eye diseases. The company has a strong pipeline of new products and services and collaborates closely with its partners to strengthen its position in the industry.

Nicox SWOT Analysis

Strengths

Nicox SA is known for its strong emphasis on innovative research and development activities. The company constantly strives to develop new and advanced solutions in the field of ophthalmology, which gives them a competitive advantage.

Nicox SA possesses a robust intellectual property portfolio, including patents and licenses for various ophthalmic products and technologies. This not only protects their innovations but also provides potential licensing and collaboration opportunities.

Weaknesses

Nicox SA heavily relies on key partnerships to conduct clinical trials, develop products, and commercialize their offerings. This dependency on external collaborations poses a risk, as any issues or disagreements with partners could negatively impact the company's operations.

Despite their technological advancements, Nicox SA has a relatively limited market presence compared to some of its competitors. This restricted market reach may restrict their growth potential and market share.

Opportunities

The global ophthalmic market is experiencing significant growth due to factors such as an aging population, rising prevalence of eye disorders, and increasing healthcare expenditure. Nicox SA can capitalize on this opportunity by introducing their innovative products to a larger customer base.

Nicox SA has the potential to enhance its market position by establishing strategic collaborations and partnerships with renowned pharmaceutical or ophthalmic companies. Such partnerships can bring together complementary expertise, resources, and networks to drive mutual growth.

Threats

The ophthalmic industry is highly competitive, with several established players and emerging companies vying for market dominance. Nicox SA faces the threat of competition, which may result in price wars, loss of market share, and reduced profitability.

As an innovative pharmaceutical company, Nicox SA must navigate complex regulatory landscapes governing drug development, clinical trials, and product approvals. Changes in regulations or delays in obtaining necessary approvals can pose significant challenges and hinder their growth prospects.

Nicox Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Nicox historical P/E ratio, EBIT multiple, and P/S ratio

Nicox annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Nicox shares outstanding

The number of shares of Nicox was 69 M in 2025. This indicates how many shares Nicox is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
88.44 M Stocks
Jan 1, 2021
88.44 M Stocks
Jan 1, 2022
44.74 M Stocks
Jan 1, 2023
50.00 M Stocks
Jan 1, 2024
69.00 M Stocks
Jan 1, 2025 (e)
69.00 M Stocks
Jan 1, 2026 (e)
69.00 M Stocks
Jan 1, 2027 (e)
69.00 M Stocks

Nicox stock splits

In Nicox's history, there have been no stock splits.

Current Nicox forecasts and price targets in July 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy88.89 % (8)
Hold11.11 % (1)
Sell0.00 % (0)
12M Price Target
1.53
Last Price
0.38
Currency
EUR
12M Return Potential
307.46 %
LTM Return
0 %

Nicox shareholder structure

% Name
4.07305%
Soleus Capital Management, L.P.
Soleus Capital Management, L.P.
3.76341%
Ocumension Therapeutics
Ocumension Therapeutics
2.45168%
HBM Healthcare Investments AG
HBM Healthcare Investments AG
0.68640%
Garufi (Michele)
Garufi (Michele)
0.22600%
Spencer Gavin T
Spencer Gavin T
0.09276%
Kaplan (Les)
Kaplan (Les)

Nicox Executives and Management Board

DM

Mr. Damian Marron

(63)

Independent Chairman of the Board · since 2002

Compensation20,779.00 EUR
MB

Mr. Marc Le Bozec

Independent Director

Compensation11,544.00 EUR
CP

Ms. Christine Placet

Independent Director

Compensation8,128.00 EUR
GS

Dr. Gavin Spencer

(54)

Chief Executive Officer, Director · since 2005

Frequently asked questions about Nicox

Nicox SA, a renowned pharmaceutical company, operates with a unique business model focused on the development and commercialization of innovative ophthalmology solutions. The company specializes in ophthalmic therapeutics and aims to improve the well-being of patients with ocular diseases. Nicox SA emphasizes research and development to create novel and effective treatments for various eye conditions, contributing to advancing eye care. With its customer-centric approach, Nicox SA strives to address unmet medical needs and provide superior healthcare solutions to patients worldwide.

All fundamentals and in-depth analysis of Nicox

Our stock analysis for Nicox stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Nicox. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Nicox Stock
Nicox Revenue→
Nicox Stock
Nicox Net Income→
Nicox Stock
Nicox P/E→
Nicox Stock
Nicox P/S→
Nicox Stock
Nicox EBIT→
Nicox Stock
Nicox Dividend→
Nicox Stock
Nicox Directors Dealings→
Nicox Stock
Nicox Stocks→
Nicox Stock
Nicox Market capitalization→
Nicox Stock
Nicox Debt→
Nicox Stock
Nicox Liabilities→
Nicox Stock
Nicox Equity→
Nicox Stock
Nicox AAQS→
Nicox Stock
Nicox Employees→
Nicox Stock
Nicox ROE→
Nicox Stock
Nicox ROA→
Nicox Stock
Nicox ROCE→
Nicox Stock
Nicox News→
Nicox Stock
Nicox Analyst Price Targets→

Health Stocks

Nidan Laboratories and HealthcareNibec CoNidhogg Resources Holding AB (publ)Niagen BioscienceNightingale Health OyjNGS GroupNihon KohdenNgl Fine ChemNingbo David Medical Device CoNGeneBio CoNingbo Menovo Pharmaceutical CoNfl Biosciences SASAll Stocks A–Z →